SCHEMBL6487298

SCHEMBL6487298

Cc1ccc(C2=C(C(=O)Nc3ccc(NCCc4ccccn4)cc3)CCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ HTT P42858 2/20 0.46
▸ RAB9A P51151 7/20 0.45
▸ NPC1 O15118 6/20 0.45
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ KDR P35968 1/20 0.44
▸ CTNNB1 P35222 2/20 0.43
▸ TCF7L2 Q9NQB0 2/20 0.43
▸ TAS1R3 Q7RTX0 1/20 0.42
▸ TAS1R1 Q7RTX1 1/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ DHODH Q02127 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489289 0.98 L3MBTL1 (0.46) L3MBTL1HTTRAB9ANPC1SMN1; SMN2
SCHEMBL6490871 0.97 L3MBTL1 (0.45) L3MBTL1HTTRAB9ANPC1SMN1; SMN2
SCHEMBL6490864 0.97 L3MBTL1 (0.45) L3MBTL1HTTRAB9ANPC1SMN1; SMN2
SCHEMBL6493547 0.97 L3MBTL1 (0.45) L3MBTL1HTTRAB9ANPC1SMN1; SMN2
SCHEMBL6491912 0.89 RAB9A (0.48) HTTRAB9ANPC1SMN1; SMN2CTNNB1
SCHEMBL6503827 0.89 HTT (0.50) L3MBTL1HTTRAB9ANPC1SMN1; SMN2
SCHEMBL6488986 0.89 TRPV1 (0.49) NAMPT
SCHEMBL6501992 0.88 CNR1 (0.54) RAB9ANPC1SMN1; SMN2KDRCTNNB1
SCHEMBL6491345 0.88 CYP1A2 (0.44) L3MBTL1HTTRAB9ANPC1SMN1; SMN2
SCHEMBL6490340 0.88 MAOA (0.47) L3MBTL1HTTRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 — — US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 — — EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 L3MBTL1 2276/4885HTT 2574/4885RAB9A 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback